The N-glycosylation module is demonstrated as a recurrent hub of context-dependent genetic interactions and combinatorial CRISPR screening as a scalable approach for identifying therapeutic targets and resistance mechanisms in oncogene-driven cancers.
Abstract
Oncogenic contexts shape synthetic lethal vulnerabilities and suppressor interactions that underlie drug resistance mechanisms, yet this context-dependence remains poorly characterized. Combinatorial CRISPR screens offer a principled approach to surface these interactions at scale with direct implications for therapeutic targeting and drug combination strategies. Using the In4mer 4-plex Cas12a knockout platform, we screened pairwise genetic interactions across RTK signaling and glycosylation networks in oncogene-stratified cancer cells (Lin et al., BioRxiv 2025), identifying hits enriched in the glycosylation machinery. Building on these findings, focused validation screens across cancer cell lines with KRAS-, BRAF-, and EGFR-drivers confirm high-effect genetic interactions concentrated in the glycosylation module across oncogenic backgrounds, revealing both synthetic lethal dependencies and suppressor interactions. Synthetic lethal candidates linking ER stress regulation and glycosyltransferase activity were supported by dependency-expression correlations in cancer cell lines, and recurrent amplification of glycosylation machinery in patient tumors is associated with poor clinical outcomes. Preliminary cell-based validation assays further corroborate a suppressor interaction, implicating a potential resistance mechanism to EGFR inhibition. Together, these findings demonstrate the N-glycosylation module as a recurrent hub of context-dependent genetic interactions and combinatorial CRISPR screening as a scalable approach for identifying therapeutic targets and resistance mechanisms in oncogene-driven cancers.
Subin Kim, Chenchu Lin, Sabriyeh Alibai, Iulia Veronica Gheorghe, Jui Hsuan Chou, Traver Hart. Combinatorial CRISPR screening reveals synthetic lethal and suppressor interactions in RTK signaling and glycosylation networks [abstract]. In: Proceedings of AACR Drug Discovery and Development (AACR D3) Conference; 2026 Jul 21-24; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(14_Suppl):Abstract nr B093.
It is demonstrated that integrated Perturb-seq experiments spanning diverse contexts enable hypotheses about gene function specific to tissue types or cancer subtypes – suggesting large-scale, genome-wide datasets would offer invaluable insight into the highly context-dependent nature of cancer biology.
Samuel Maffa, Isabella A. Boyle, Lie Ward et al.· bioRxiv· 0 citations
Genome-wide CRISPR screens have systematically identified genes required for cancer cell survival, yet these studies are typically performed under standardized conditions that do not fully recapitulate the physiological stresses encountered within the tumor microenvironment. In a recent issue of Nature Genetics, Cherui...
Zihan Ning, Guangchuan Wang· Cancer Research· 0 citations
It is hypothesized that genome-wide CRISPRa screening will uncover subtype-specific genetic dependencies and drug resistance mechanisms, offering novel therapeutic insights in leukemia subtype biology, guiding future personalized treatment strategies.
Jeffrey Sullivan, Xiaozen Wen, Gabriela Flores-Vargas et al.· Journal of Immunology· 0 citations
Key methodological steps for achieving high-efficiency lentiviral transduction and selection are described, enabling the successful application of EPIKOL CRISPR screens in chemoresistant TNBC models.
O. Yedier-Bayram, Elif Ayca Guvener, T. Bagci-Onder· Journal of Visualized Experi...· 0 citations
The study suggests that the inhibition of the Wnt/LEF1 axis is associated with the potential activation of a compensatory survival mechanism, involving the NF-kappa B/AP-1 pathway.
I. Alhamadani, Mohammad Alzeyadi· Asian Pacific Journal of Can...· 0 citations
It is demonstrated that machine learning applied to transcriptomic data can uncover novel cancer vulnerabilities and actionable targets in individual tumors, even in the absence of functional screening, which may represent a scalable approach to advance precision oncology in rare and/or under-characterized cancer types...
Ananthan Sadagopan, Bingchen Li, Jiao Li et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.